Analyst Price Target is $41.00
▲ +3,153.97% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Angion Biomedica in the last 3 months. The average price target is $41.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 3,153.97% upside from the last price of $1.26.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Angion Biomedica.
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.